Opinion|Videos|November 12, 2024
Advances in Menopause Treatment: A Focus on the Neurokinin Pathway
Key Takeaways
- Neurokinin is crucial in the pathophysiology of vasomotor symptoms linked to menopause, offering a target for novel treatments.
- Fezolinetant, a nonhormonal agent, antagonizes neurokinin-3 receptors to treat moderate to severe VMS.
Panelists discuss the role of neurokinin in the pathophysiology of vasomotor symptoms (VMS) and examine the mechanisms of action of novel nonhormonal agents such as fezolinetant and elinzanetant, highlighting the advantages of targeting neurokinin pathways over traditional hormonal treatments and their potential to address related menopause issues such as mood disturbances and sleep disorders.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- (PINKERTON) What is the role of neurokinin in the pathophysiology of vasomotor symptoms?
- (SMITH) Fezolinetant is a nonhormonal novel agent now available for the treatment of moderate to severe VMS due to menopause. How is moderate to severe VMS defined? What is the mechanism of action of fezolinetant?
- (PINKERTON) Elinzanetant is another nonhormonal, novel agent recently submitted for FDA approval for the treatment of moderate to severe VMS. What is the mechanism of action of elinzanetant, and how might the unique mechanism of NK1 antagonism help to treat other menopause-related conditions, such as mood disturbances or sleep disorders?
- (FIFFICK) What are the advantages of targeting the neurokinin pathways in menopause treatment compared with traditional hormonal approaches?
Advertisement
Related to this article
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.
Medicare Advantage plans have varied motivations, strategies, and aspirations for addressing health-related social needs among home health beneficiaries, highlighting a need to expand the scope of supplemental benefits.
2026 Nobel Prize in Medicine honors optogenetics pioneers who turn algae light-sensing protein into neural switches, transforming brain mapping and enabling vision-restoration trials.
Medicare's Transforming Episode Accountability Model is projected to save $46.6 million by 2030, with safety-net hospitals potentially receiving the highest reconciliation payments.
A comparison of 2013 and 2022 data shows that cancer costs are not uniformly rising. Costs decreased for metastatic colorectal cancer but increased for both metastatic non–small cell lung cancer and multiple myeloma.
Employer-mandated enrollment in a high-deductible health plan did not reduce use of oral targeted anticancer medications among patients commercially insured between 2007 and 2021.
We identify the health system characteristics associated with greater or lesser documentation of patients’ social determinants of health.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
3
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
4
Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment
5